about
Antibiotics in the clinical pipeline at the end of 2015.Chemical philanthropy: a path forward for antibiotic discovery?Design and synthesis of phosphotyrosine mimetics.Drug discovery and protein tyrosine phosphatases.A new antibiotic with potent activity targets MscL.Metronidazole-triazole conjugates: activity against Clostridium difficile and parasitesClostridium difficile drug pipeline: challenges in discovery and development of new agentsDiscovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.Mucin Binding Reduces Colistin Antimicrobial Activity.Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B.Contribution of Amphipathicity and Hydrophobicity to the Antimicrobial Activity and Cytotoxicity of β-Hairpin PeptidesNitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.Resolving biofilm infections: current therapy and drug discovery strategies.Lipoamino acids as major components of absorption promoters in drug delivery.Antibiotics in the clinical pipeline in 2013.Glycopeptide antibiotics: back to the future.Cell- and biomarker-based assays for predicting nephrotoxicity.Short cationic lipopeptides as effective antibacterial agents: Design, physicochemical properties and biological evaluation.Old dogs and new tricks in antimicrobial discovery.Unusual Amino Acids in Medicinal Chemistry.Polishing the tarnished silver bullet: the quest for new antibiotics.Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.Helping Chemists Discover New Antibiotics.Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cellsFluorescent Trimethoprim Conjugate Probes To Assess Drug Accumulation in Wild Type and Mutant Escherichia coliAnti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.Institutional profile: Community for Open Antimicrobial Drug Discovery - crowdsourcing new antibiotics and antifungals.Antibacterial serrulatane diterpenes from the Australian native plant Eremophila microtheca.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.Developments in Glycopeptide Antibiotics.Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.Surface Ligand Density of Antibiotic-Nanoparticle Conjugates Enhances Target Avidity and Membrane Permeabilization of Vancomycin-Resistant Bacteria.Structure-Activity and -Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1.Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria.Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant Klebsiella pneumoniae.Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.Enhancement of antibiotic-activity through complexation with metal ions - Combined ITC, NMR, enzymatic and biological studies.Fluorescent Antibiotics: New Research Tools to Fight Antibiotic Resistance.Self-assembling lipopeptides with a potent activity against Gram-positive bacteria, including multidrug resistant strains.Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.
P50
Q30249262-D9AE2865-1943-481F-A2F2-13F06ACD99AFQ30489379-0C81D8F1-3C7A-4E7D-BC90-F40A5FFACA6DQ33187230-1B4AB5BB-47FF-4424-BB92-158D6545BF8EQ33466443-A0D4F1BE-0C10-417C-A3E1-E4E97A95E9D5Q35602329-D00877C9-E2C5-4736-8799-8DC9AC1E3446Q35676340-F54267F5-8574-4BCB-9111-CAECBF547A8EQ35846436-FC69F55E-6F0D-4046-99C2-66DEFB0DDE9EQ35997737-FDA3BEC6-025A-4119-A2AD-7ECB9DE22799Q36076096-4A69E06D-0411-4193-ADF6-002CA27CADBFQ36641728-A8204670-8AE1-4363-A71A-BCD397413FBCQ37000571-C4630AD7-C42F-44B8-83D1-2F45EF0B695BQ37037261-9EFB7320-96C1-494C-8F1C-3EFD1E752D54Q38015964-89F71E93-44C1-49DF-BB1C-411BBA692E4EQ38029091-A46FF3AB-A15C-49D3-8D3B-D8D7BFB14126Q38133967-93AE085C-5EB1-46E0-B9B0-82F8E9F6C2CAQ38239460-F61819BC-A27E-4C5C-860B-C2EF37DAF482Q38266417-8E9534CF-1AD0-4E8E-A3F3-ED01A58300EAQ38780506-5A543F88-A227-4CC2-BCAF-7DB6277AFCE1Q38810607-33962061-2D1F-440F-9127-D758753EDB35Q38944883-37F10237-476F-48BB-8DF8-04C46F3F58CAQ39160499-DCAAF328-BD14-41E0-B5F4-F39FA5D65FDCQ39278070-A94C31F3-BDB2-4C44-B81E-710182CA4EEFQ41119417-C1E96651-AECC-4CD6-A9F1-4E9AEE7AAA74Q41359427-F32CD629-5774-4D48-B1AE-A085CD09F962Q41484434-24B031BF-6ACA-463C-B372-1EB0B049EB36Q41858535-EBAEA6CE-4FE2-4862-85D3-63F4B3365D37Q42335280-E37BCAA8-5F41-4A2B-8DF7-238ADCBC91A1Q44249164-479B8B39-41F1-4C87-A7CA-10E6D8A10AB4Q47236751-96D53D8F-1001-4035-AD3E-495B7792F876Q47715119-D35F3E8D-D4BA-48F6-995D-3BFA62405AE2Q48146758-4CD0CC77-887C-4E8A-89FA-B3C97E1F6E8DQ48160320-1110B3F2-C7C9-4061-BF3D-A1727F8836AFQ48269676-3DC57992-46EE-4E38-B324-1A5AAC2BB789Q49359694-3ECB85A4-0118-40CB-8485-72196CB2D78AQ50066715-73EF3FAF-0A47-487D-96D8-4233B55561BEQ51028883-7DBDD03C-F8D2-4330-886F-9D1643EFAD1EQ51255285-35EC064F-2835-4924-849F-FAE933CFA5F3Q51417333-050162D2-5BA9-4D28-8DC4-8D127E5887A9Q53795891-B6E3597E-D0C3-4E87-9EDF-52FA9E1CFCA5Q55711857-B0AF7F53-66DA-42AB-87F9-C23E3C607172
P50
description
researcher ORCID ID = 0000-0001-9447-2292
@en
wetenschapper
@nl
name
Mark Blaskovich
@ast
Mark Blaskovich
@en
Mark Blaskovich
@es
Mark Blaskovich
@nl
type
label
Mark Blaskovich
@ast
Mark Blaskovich
@en
Mark Blaskovich
@es
Mark Blaskovich
@nl
prefLabel
Mark Blaskovich
@ast
Mark Blaskovich
@en
Mark Blaskovich
@es
Mark Blaskovich
@nl
P106
P1153
6603840133
P21
P31
P496
0000-0001-9447-2292